Department of Neurosurgery.
China National Clinical Research Center for Neurological Diseases.
Int J Surg. 2023 Jul 1;109(7):1900-1909. doi: 10.1097/JS9.0000000000000341.
BACKGROUND: Brain arteriovenous malformations (AVMs) account for 25% of hemorrhagic strokes in young adults. Although embolization has been widely performed as a stand-alone procedure to cure brain AVM, it is undermined whether patients benefit from this treatment. This study aimed to compare the long-term outcome of hemorrhagic stroke or death in patients with either conservative management or stand-alone embolization for AVM. METHODS: The study population was derived from a nationwide multicenter prospective collaboration registry (the MATCH registry) between August 2011 and August 2021. The propensity score-matched survival analysis was performed in the overall and stratified AVM cases (unruptured and ruptured), respectively, to compare the long-term outcome of hemorrhagic stroke or death, and neurological status. The efficacy of distinct embolization strategies was also evaluated. Hazard ratios (HRs) with 95% CI were calculated using Fine-Gray competing risk models. RESULTS: Of the 3682 consecutive AVMs, 906 underwent either conservative management or embolization as the stand-alone management strategy. After propensity score matching, a total of 622 (311 pairs) patients constituted an overall cohort. The unruptured and ruptured subgroups were composed of 288 cases (144 pairs) and 252 cases (126 pairs), respectively. In the overall cohort, embolization did not prevent long-term hemorrhagic stroke or death compared with conservative management [2.07 vs. 1.57 per 100 patient-years; HR, 1.28 (95% CI, 0.81-2.04)]. Similar results were maintained in both unruptured AVMs [1.97 vs. 0.93 per 100 patient-years; HR, 2.09 (95% CI, 0.99-4.41)] and ruptured AVMs [2.36 vs. 2.57 per 100 patient-years; HR, 0.76 (95% CI, 0.39-1.48)]. Stratified analysis showed that the target embolization might be beneficial for unruptured AVMs [HR, 0.42 (95% CI, 0.08-2.29)], while the curative embolization improved the outcome of ruptured AVMs [HR, 0.29 (95% CI, 0.10-0.87)]. The long-term neurological status was similar between these two strategies. CONCLUSIONS: This prospective cohort study did not support a substantial superiority of embolization over conservative management for AVMs in preventing long-term hemorrhagic stroke or death.
背景:脑动静脉畸形(AVM)占青年成人出血性中风的 25%。尽管栓塞已被广泛用作治疗脑 AVM 的独立治疗方法,但患者是否从中受益仍存在争议。本研究旨在比较单独采用保守治疗或栓塞治疗的 AVM 患者发生出血性中风或死亡的长期结果。
方法:该研究人群来自 2011 年 8 月至 2021 年 8 月期间进行的一项全国多中心前瞻性协作登记研究(MATCH 登记研究)。分别对整体和分层 AVM 病例(未破裂和破裂)进行倾向评分匹配生存分析,以比较出血性中风或死亡以及神经状态的长期结果。还评估了不同栓塞策略的疗效。使用 Fine-Gray 竞争风险模型计算具有 95%置信区间的风险比(HR)。
结果:在连续的 3682 例 AVM 中,906 例行单独采用保守治疗或栓塞治疗。进行倾向评分匹配后,共有 622 例(311 对)患者构成了整体队列。未破裂和破裂亚组分别由 288 例(144 对)和 252 例(126 对)患者组成。在整体队列中,与保守治疗相比,栓塞治疗并未预防长期出血性中风或死亡[每 100 患者年分别为 2.07 例和 1.57 例;HR,1.28(95%CI,0.81-2.04)]。在未破裂 AVM 中[每 100 患者年分别为 1.97 例和 0.93 例;HR,2.09(95%CI,0.99-4.41)]和破裂 AVM 中[每 100 患者年分别为 2.36 例和 2.57 例;HR,0.76(95%CI,0.39-1.48)]也得到了相似的结果。分层分析显示,靶向栓塞可能对未破裂 AVM 有益[HR,0.42(95%CI,0.08-2.29)],而治愈性栓塞可改善破裂 AVM 的结局[HR,0.29(95%CI,0.10-0.87)]。这两种策略的长期神经状态相似。
结论:本前瞻性队列研究不支持栓塞治疗在预防 AVM 患者长期出血性中风或死亡方面优于保守治疗。
J Neurol Neurosurg Psychiatry. 2025-7-16
J Neurosurg Pediatr. 2025-4-25
J Neuroendovasc Ther. 2025
Interv Neuroradiol. 2024-9-2
Front Neurol. 2023-8-3
J Neurointerv Surg. 2022-11